Differential adverse event profiles associated with BCG as a preventive tuberculosis vaccine or therapeutic bladder cancer vaccine identified by comparative ontology-based VAERS and literature meta-analysis

PLoS ONE

Volumn 11, Issue 10, 2016, Pages

  Xie, Jiangan ^a,b   Codd, Christopher ^c   Mo, Kevin ^c   He, Yongqun ^b  

^a CHONGQING UNIVERSITY   (China)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; BCG VACCINE; BILIRUBIN; C REACTIVE PROTEIN; CREATININE; HEMOGLOBIN; CANCER VACCINE;

ABSCESS; ADVERSE OUTCOME; AGE; ALLERGY; ANEMIA; ANOREXIA; APNEA; ARTHRALGIA; ARTICLE; ASTHENIA; AXILLARY MASS; BACKACHE; BACTERIAL INFECTION; BCG VACCINATION; BILIRUBIN BLOOD LEVEL; BLADDER CANCER; BLADDER SPASM; BLEEDING; BRADYCARDIA; CACHEXIA; CANCER IMMUNIZATION; CHEMICAL CYSTITIS; CHILL; COLD SWEAT; COUGHING; CREATININE BLOOD LEVEL; CYANOSIS; DEPRESSION; DIARRHEA; DISABILITY; DISEASE ASSOCIATION; DIZZINESS; DRUG SAFETY; DYSURIA; ECZEMA; EDEMA; EPISTAXIS; ERYTHEMA; FATIGUE; FEVER; FLU LIKE SYNDROME; FLUSHING; GASTROENTERITIS; GASTROINTESTINAL PAIN; GRANULOMA; GRANULOMATOUS PROSTATITIS; HEADACHE; HEMATOMA; HEMATURIA; HEMOGLOBIN BLOOD LEVEL; HEPATITIS; HEPATOSPLENOMEGALY; HUMAN; HYPERTENSION; HYPOCALCEMIA; HYPOPHAGIA; IMMUNE DEFICIENCY; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INJECTION SITE ULCER; INTUSSUSCEPTION; IRRITABILITY; JOINT SWELLING; KELOID; KIDNEY PAIN; LIVER ABSCESS; LOWER ABDOMINAL PAIN; LUNG DISEASE; LUNG INFECTION; LYMPHADENITIS; LYMPHADENOPATHY; MALAISE; MENINGITIS; META ANALYSIS; MUCOCUTANEOUS LYMPH NODE SYNDROME; MUSCLE HYPOTONIA; MUSCULOSKELETAL PAIN; MYALGIA; NECROSIS; NOCTURIA; NOSE OBSTRUCTION; OSTEITIS; OSTEOMYELITIS; PANCYTOPENIA; PAPULE; PARESTHESIA; PNEUMONIA; POLLAKISURIA; PROSTATITIS; PRURITUS; PSYCHOMOTOR RETARDATION; PURPURA; PUSTULE; PYURIA; RASH; RECTUM HEMORRHAGE; RESPIRATORY FAILURE; RESPIRATORY TRACT DISEASE; RESPIRATORY TRACT INFECTION; SCAR; SEDIMENTATION RATE; SEIZURE; SEPSIS; SKIN BURNING SENSATION; SKIN DEFECT; SKIN DISCOLORATION; SKIN EXFOLIATION; SKIN ULCER; SPLENOMEGALY; SUDDEN DEATH; SYSTEMATIC REVIEW; TACHYCARDIA; THROMBOCYTOPENIA; THROMBOCYTOPENIC PURPURA; TUBERCULOSIS; URETHRAL PAIN; URINARY FREQUENCY; URINARY TRACT INFECTION; URINARY URGENCY; URINE INCONTINENCE; URTICARIA; VASCULITIS; FACTUAL DATABASE; IMMUNOLOGY; URINARY BLADDER NEOPLASMS;

BCG VACCINE; C-REACTIVE PROTEIN; CANCER VACCINES; DATABASES, FACTUAL; DYSURIA; HUMANS; LYMPHADENOPATHY; PNEUMONIA; SKIN ULCER; TUBERCULOSIS VACCINES; URINARY BLADDER NEOPLASMS;

EID: 84992437291     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0164792     Document Type: Article

References (42)

1. Luca S, Mihaescu T. History of BCG Vaccine. Maedica. 2013; 8(1):53-8. PMID: 24023600; PubMed Central PMCID: PMC3749764.
2. Andersen P, Doherty TM. The success and failure of BCG-implications for a novel tuberculosis vaccine. Nature reviews Microbiology. 2005; 3(8):656-62. doi: 10.1038/nrmicro1211 PMID: 16012514.
3. WHO. Weekly epidemiological record: releve epidemiologique hebdomadaire. World Health Organization2006.
4. Paterson DL, Patel A. Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: review of complications and their treatment. The Australian and New Zealand journal of surgery. 1998; 68 (5):340-4. PMID: 9631906.
5. Herr HW, Moralest A. History of bacillus Calmette-Guerin and bladder cancer: An immunotherapy success story. J Urology. 2008; 179(1):53-6. doi: 10.1016/j.juro.2007.08.122. WOS:000251650200012. PMID: 17997439
6. Pearl R. Cancer and tuberculosis. Am J Hygiene. 1929; 9:97.
7. Turnbull F, McIntyre P, Achat H, Wang H, Stapledon R, Gold M, et al. National study of adverse reactions after vaccination with bacille Calmette-Gue rin. Clinical infectious diseases. 2002; 34(4):447-53. doi: 10.1086/338462 PMID: 11797170
8. Toida I, Nakata S. Severe adverse reactions after vaccination with Japanese BCG vaccine: a review. Kekkaku: Tuberculosis. 2007; 82(11):809-24. PMID: 18078106
9. FDA. What is a Serious Adverse Event? Available: http://www.fda.gov/Safety/MedWatch/ HowToReport/ucm053087.htm (Accessed: 5th October 2016).
10. Chen RT, Rastogi SC, Mullen JR, Hayes SW, Cochi SL, Donlon JA, et al. The vaccine adverse event reporting system (VAERS). Vaccine. 1994; 12(6):542-50. PMID: 8036829
11. Iskander J, Pool V, Zhou W, English-Bullard R. Data mining in the US using the vaccine adverse event reporting system. Drug safety. 2006; 29(5):375-84. PMID: 16689554
12. Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug safety. 1999; 20(2):109-17. Epub 1999/03/19. PMID: 10082069.
13. Brown EG. Methods and pitfalls in searching drug safety databases utilising the Medical Dictionary for Regulatory Activities (MedDRA). Drug safety. 2003; 26(3):145-58. Epub 2003/02/13. 260302 [pii]. PMID: 12580645.
14. He YQ, Sarntivijai S, Lin Y, Xiang ZS, Guo A, Zhang S, et al. OAE: The Ontology of Adverse Events. J Biomed Semant. 2014; 5:29. WOS:000343711400001.
15. Sarntivijai S, Xiang ZS, Shedden KA, Markel H, Omenn GS, Athey BD, et al. Ontology-Based Combinatorial Comparative Analysis of Adverse Events Associated with Killed and Live Influenza Vaccines. Plos One. 2012; 7(11):e49941. WOS:000312601700028. doi: 10.1371/journal.pone.0049941 PMID: 23209624
16. Sarntivijai S, Zhang S, Jagannathan DG, Zaman S, Burkhart KK, Omenn GS, et al. Linking MedDRA®-Coded Clinical Phenotypes to Biological Mechanisms by the Ontology of Adverse Events: A Pilot Study on Tyrosine Kinase Inhibitors. Drug safety. 2016:1-11.
17. He Y. Ontology-based vaccine and drug adverse event representation and theory-guided systematic causal network analysis toward integrative pharmacovigilance research. Current Pharmacology Reports. 2016; 2(3):113-28. doi: 10.1007/s40495-016-0055-0 PMID: 27458549
18. Evans SJW, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiology and Drug Safety. 2001; 10 (6):483-6. WOS:000173426600001. doi: 10.1002/pds.677 PMID: 11828828
19. Yates F. Contingency tables involving small numbers and the χ2 test. Supplement to the Journal of the Royal Statistical Society. 1934; 1:217-35.
20. Banks D, Woo EJ, Burwen DR, Perucci P, Braun MM, Ball R. Comparing data mining methods on the VAERS database. Pharmacoepidem Dr S. 2005; 14(9):601-9. WOS:000231913600002.
21. Rubin DL, Noy NF, Musen MA. Protege: a tool for managing and using terminology in radiology applications. Journal of digital imaging. 2007; 20 Suppl 1:34-46. doi: 10.1007/s10278-007-9065-0 PMID: 17687607; PubMed Central PMCID: PMC2039856.
22. Xiang Z, Courtot M, Brinkman RR, Ruttenberg A, He Y. OntoFox: web-based support for ontology reuse. BMC research notes. 2010; 3(1):175.
23. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Systematic reviews. 2015; 4(1):1.
24. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Annals of internal medicine. 2009; 151(4):W-65.
25. He Y. Ontology-supported research on vaccine efficacy, safety and integrative biological networks. Expert review of vaccines. 2014; 13(7):825-41. doi: 10.1586/14760584.2014.923762 PMID: 24909153; PubMed Central PMCID: PMC4815432.
26. Smith B. Invited Papers from the 10th International Conference in Logic Methodology and Philosophy of Science, Oviedo, Spain [Internet]2003.
27. FDA. BCG vaccine for percutaneous use-U.S. Food and Drug Administration. Available: http://www. fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM202934.pdf (Aceessed 5 October 2016).
28. FDA. BCG live for intravesical use-U.S. Food and Drug Administration. Available: http://www.fda. gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM163039.pdf (Aceessed 5 October 2016).
29. Clothier HJ, Hosking L, Crawford NW, Russell M, Easton ML, Quinn JA, et al. Bacillus Calmette-Guerin (BCG) vaccine adverse events in Victoria, Australia: analysis of reports to an enhanced passive surveillance system. Drug safety. 2015; 38(1):79-86. doi: 10.1007/s40264-014-0248-6 PMID: 25475539.
30. Dourado I, Rios MH, Pereira SM, Cunha SS, Ichihara MY, Goes JC, et al. Rates of adverse reactions to first and second doses of BCG vaccination: results of a large community trial in Brazilian schoolchildren. The international journal of tuberculosis and lung disease: the official journal of the International Union against Tuberculosis and Lung Disease. 2003; 7(4):399-402. PMID: 12729348.
31. Mayet A, Duron S, Meynard JB, Koeck JL, Deparis X, Migliani R. Surveillance of adverse events following vaccination in the French armed forces, 2011-2012. Public health. 2015; 129(6):763-8. doi: 10. 1016/j.puhe.2015.03.003 PMID: 25890634.
32. Bolger T, O'Connell M, Menon A, Butler K. Complications associated with the bacille Calmette-Guerin vaccination in Ireland. Archives of disease in childhood. 2006; 91(7):594-7. doi: 10.1136/adc.2005. 078972 PMID: 16547086; PubMed Central PMCID: PMC2082825.
33. Thoon KC, Soh SB, Liew WK, Gunachandran A, Tan NW, Chong CY, et al. Active surveillance of adverse events following childhood immunization in Singapore. Vaccine. 2014; 32(39):5000-5. doi: 10.1016/j.vaccine.2014.07.020 PMID: 25045811.
34. Wu WD, Liu DW, Li L. [Literature review of adverse events following immunization of Bacillus Calemtte-Guerin vaccine]. Zhongguo yi miao he mian yi. 2009; 15(6):491-5. PMID: 20518321.
35. Bricks LF. Percutaneous or intradermal BCG vaccine? Jornal de pediatria. 2004; 80(2):93-8. PMID: 15079177
36. Davids V, Hanekom WA, Mansoor N, Gamieldien H, Sebastian JG, Hawkridge A, et al. The effect of bacille Calmette-Guerin vaccine strain and route of administration on induced immune responses in vaccinated infants. Journal of Infectious Diseases. 2006; 193(4):531-6. doi: 10.1086/499825 PMID: 16425132
37. Redelman-Sidi G, Glickman MS, Bochner BH. The mechanism of action of BCG therapy for bladder cancer-a current perspective. Nature reviews Urology. 2014; 11(3):153-62. doi: 10.1038/nrurol. 2014.15 PMID: 24492433.
38. Centers for Disease C, Prevention. Addition of severe combined immunodeficiency as a contraindication for administration of rotavirus vaccine.MMWR Morbidity and mortality weekly report. 2010; 59 (22):687-8. PMID: 20535093.
39. Kohl KS, Bonhoeffer J, Braun MM, Chen RT, Duclos P, Heijbel H, et al. The Brighton Collaboration: Creating a Global Standard for Case Definitions (and Guidelines) for Adverse Events Following Immunization. In: Henriksen K, Battles JB, Marks ES, Lewin DI, editors. Advances in Patient Safety: From Research to Implementation (Volume 2: Concepts and Methodology). Advances in Patient Safety. Rockville (MD)2005.
40. Singleton JA, Lloyd JC, Mootrey GT, Salive ME, Chen RT. An overview of the vaccine adverse event reporting system (VAERS) as a surveillance system. VAERS Working Group. Vaccine. 1999; 17 (22):2908-17. PMID: 10438063.
41. He Y, Rappuoli R, De Groot AS, Chen RT. Emerging vaccine informatics. J Biomed Biotechnol. 2010; 2010:218590. Epub 2010/01/01. doi: 10.1155/2010/218590 PMID: 21772787; PubMed Central PMCID: PMC3134832.
42. Brown SH, Elkin PL, Bauer BA, Wahner-Roedler D, Husser CS, Temesgen Z, et al. SNOMED CT: utility for a general medical evaluation template. AMIA Annu Symp Proc. 2006:101-5. Epub 2007/01/24. 86443 [pii]. PMID: 17238311.